Background: Childhood bronchiolitis obliterans (CBO) is an infrequent but severe disease, characterized by persistent obstructive respiratory symptoms after an acute episode of bronchiolitis. Its etiology is mostly postviral, especially in developing countries. Pathologically, CBO is characterized as constrictive-type BO. The pathogenesis of this disease is poorly understood and there is no specific treatment. Animal models could help to better understand the sequence of events culminating in bronchiolar obliteration and serve as basis for experimental therapeutic research. Objectives: In this study, we adapted the nitric acid (NA) technique to develop a suitable model to study CBO in rats. Methods: We have intratracheally instilled 0.5% NA or saline and studied the histological lesions on days 2, 7, 14 and 30. NA-instilled animals developed a sequence of bronchiolar lesions that included necrotizing bronchiolitis, proliferative (PROL) bronchiolar lesions and constricitive (CONS) bronchiolar lesions with bronchiectasis, mucostasis and macrophagic accumulation. Results: The frequency of PROL lesions decreased and that of the CONS lesions increased, with a statistically significant difference at the sacrifice days, except for day 7 (PROL vs. CONS lesions day 2: p = 0.001; PROL vs. CONS lesions day 7: p = 0.38; PROL vs. CONS lesions day 14: p < 0.001; PROL vs. CONS lesions day 30: p < 0.001). Conclusions: We conclude that this model presents histological similarities with the histological picture of CBO, being suitable for further developmental and therapeutic experimental research in this field.

1.
Colby TV: Bronchiolitis. Pathologic considerations. Am J Clin Pathol 1998;109:101–109.
2.
Fischer GB, Teper A, Colom AJ: Acute viral bronchiolitis and its sequelae in developing countries. Paediatr Respir Rev 2002;3:298–302.
3.
Zhang L, Irion K, Kozakewich H, Reid L, Camargo JJ, Porto NS, Abreu e Silva F: Clinical course of postinfectious bronchiolitis obliterans. Pediatr Pulmonol 2000;29:341–350.
4.
Ryu JH, Myers JL, Swensen SJ: Bronchiolar disorders. Am J Respir Crit Care Med 2003;168:1277–1292.
5.
Mauad T, Dolhnikoff M, et al: Histology of childhood bronchiolitis obliterans. Pediatr Pulmonol 2002;33:466–474.
6.
Mauad T, Schadewijk AV, Schrumpf J, Hack CE, Fernezlian S, Garippo AL, Ejzenberg B, Hiemstra PS, Rabe KF, Dolhnikoff M, The Sao Paulo BO Study Group: Lymphocytic inflammation in childhood bronchiolitis obliterans. Pediatr Pulmonol 2004;38:233–239.
7.
Hardy KA: Childhood bronchiolitis obliterans; in Epler GR (ed): Diseases of the Bronchioles. New York, Raven Press, 1994, pp 415–426.
8.
Slauson DO, Hahn FF: Criteria for development of animal models of diseases of the respiratory system. Am J Pathol 1980;101:S103–S122.
9.
Clyde WA Jr: Experimental models for study of common respiratory viruses. Environ Health Perspect 1980;35:107–112.
10.
Bramley AM, Khan MA, Manson HE, Hegele RG: Development of respiratory syncytial virus ‘bronchiolitis’ in guinea pigs does not reflect an allergic predisposition in the host. Chest 2003;124:671–681.
11.
Higuchi T, Jaramillo A, Kaleem Z, Patterson GA, Mohanakumar T: Different kinetics of obliterative airway disease development in heterotopic murine tracheal allografts induced by CD4+ and CD8+ T cells. Transplantation 2002;74:646–651.
12.
Maasilta PK, Salminen US, Lautenschlager IT, Taskinen EI, Harjula AL: Immune cells and immunosuppression in a porcine bronchial model of obliterative bronchiolitis. Transplantation 2001;72:998–1005.
13.
Castleman WL: Bronchiolitis obliterans and pneumonia induced in young dogs by experimental adenovirus infection. Am J Pathol 1985;119:495–504.
14.
Moran T, Hellstrom R: Bronchiolitis obliterans. An experimental study of the pathogenesis and the use of cortisone in modification of the lesions. Arch Pathol 1958;66:691–707.
15.
Coalson J, Collins JF: Nitric acid-induced injury in the hamster lung. Br J Exp Path 1985;66:205–215.
16.
Chang AB, Masel JP, Masters B: Post-infectious bronchiolitis obliterans: Clinical, radiological and pulmonary function sequelae. Pediatr Radiol 1998;28:23–29.
17.
Foster JR, Cottrell RC, Herod IA, Atkinson HA, Miller K: A comparative study of the pulmonary effects of NO2 in the rat and hamster. Br J Exp Pathol 1985;66:193–204.
18.
Lam C, Kattan M, Collins A, Kleinerman J: Long-term sequelae of bronchiolitis induced by nitrogen dioxide in hamsters. Am Rev Respir Dis 1983;128:1020–1023.
19.
Stavert DM, Archuleta DC, Holland LM, Lehnert BE: Nitrogen dioxide exposure and development of pulmonary emphysema. J Toxicol Environ Health 1986;17:249–267.
20.
Svetlecic J, Molteni A, Herndon B: Bronchiolitis obliterans induced by intratracheal papaverine: A novel animal model. Lung 2004;182:119–134.
21.
Lai RS, Chiang AA, Wu MT, Wang JS, Lai NS, Lu JY, Ger LP, Roggli V: Outbreak of bronchiolitis obliterans associated with consumption of Sauropus androgynus in Taiwan. Lancet 1996;348:83–85.
22.
Lindsey JR, Baker HJ, Overcash RG, Cassell GH, Hunt CE: Murine chronic respiratory disease. Significance as a research complication and experimental production with Mycoplasma pulmonis. Am J Pathol 1971;64:675–708.
23.
Fukuda Y, Mochimaru H, Terasaki Y, Kawamoto M, Kudoh S: Mechanism of structural remodeling in pulmonary fibrosis. Chest 2001;120:41S–43S.
24.
Kim CK, Kim SW, Kim JS, Koh YY, Cohen AH, Deterding RR, White CW: Bronchiolitis obliterans in the 1990s in Korea and the United States. Chest 2001;120:1101–1106.
25.
Yalcin E, Dogru D, Haliloglu M, Ozcelik U, Kiper N, Gocmen A: Postinfectious bronchiolitis obliterans in children: Clinical and radiological profile and prognostic factors. Respiration 2003;70:371–375.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.